Press Releases

April 16, 2024
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials

Read more...

April 3, 2024
Asher Bio Announces Publications in Cancer Discovery Highlighting the Differentiated Profile of AB248, its CD8+ T Cell Selective IL-2 Product Candidate
October 31, 2023
Asher Bio Presents Promising New Preclinical Data for Cis-targeted Cancer Immunotherapy AB821 at SITC Annual Meeting
June 22, 2023
Asher Bio Presents New Preclinical Data Further Supporting Development of AB359 for Chronic Hepatitis B Virus at EASL International Liver Conference 2023
March 14, 2023
Asher Bio to Highlight Pipeline Programs in Presentations at AACR Annual Meeting 2023
January 17, 2023
Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid Tumors
January 5, 2023
Asher Bio Appoints Independent Director Elaine Sun to its Board
December 12, 2022
Asher Bio Presents New Preclinical Data at ASH Applying Cis-Targeted Cytokines to Enhance CAR-T Cell Therapies
November 10, 2022
Asher Bio Presents New Preclinical Data at SITC 2022 Further Supporting Advancement of AB248 and AB821 as Highly Differentiated Cis-targeted Cancer Immunotherapies
November 4, 2022
Asher Bio Presents New Data Demonstrating Preclinical Proof-of-Concept for AB359, a Highly Selective CD8-Targeted IL-2 Therapy, for Chronic Hepatitis B (HBV) at AASLD 2022
November 3, 2022
Asher Bio to Present New Preclinical Data for Selective Support of CAR-T Cell Therapies by Cis-Targeted IL-2 and IL-21 Cytokines at ASH 2022
October 21, 2022
Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022
October 5, 2022
Asher Bio to Present New Preclinical Data for CD8+ T Cell Targeted Immunotherapies, AB248 and AB821, at SITC 2022
July 6, 2022
Asher Bio Appoints Independent Director Bob Deresiewicz, M.D., to its Board
June 13, 2022
Asher Bio Appoints Andrea Pirzkall, M.D., as Chief Medical Officer
June 1, 2022
Asher Bio Announces Clinical Trial Collaboration with Merck to Evaluate AB248 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
April 8, 2022
Asher Bio to Present New Preclinical Data Demonstrating Differentiated Profile of AB248, its Lead Cis-targeted IL-2 Immunotherapy, at AACR Annual Meeting
April 8, 2022
Asher Bio to Unveil Two New Immunotherapy Programs, a CD8+ T Cell Targeted IL-21 and a Cis-Targeted IL-2 for Cell Therapy Augmentation, at AACR Annual Meeting
March 8, 2022
Asher Bio to Showcase Continued Progress with Lead Program AB248 and Growing Pipeline of Precisely-Targeted Immunotherapies at AACR Annual Meeting 2022
February 14, 2022
Asher Bio Appoints Ian T. Clark to its Board of Directors
February 4, 2022
Asher Bio to Present at Upcoming Investor Conferences
January 24, 2022
Asher Bio Expands Leadership Team with Three Key Appointments
January 5, 2022
Asher Bio to Present at 40th Annual J.P. Morgan Healthcare Conference
December 15, 2021
Asher Bio Showcases Versatility and Broad Applicability of Cis-Targeting Technology for Precision Immunotherapies at Antibody Engineering Conferences
November 15, 2021
Asher Bio to Present at Upcoming Investor Conferences
November 12, 2021
Asher Bio Announces New Preclinical Data Demonstrating Best-in-Class Potential of AB248, its Lead Cis-targeted IL-2 Immunotherapy
October 1, 2021
Asher Bio to Present Preclinical Proof-of-Concept Data for AB248, a Highly Selective CD8-targeted IL-2 Therapy, at SITC 2021
September 2, 2021
Asher Bio to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
September 1, 2021
Asher Bio Closes $108 Million Series B Financing
June 14, 2021
Asher Bio Appoints Leading Experts in Immunology, Oncology and Protein Therapeutics to its Scientific Advisory Board
March 23, 2021
Asher Bio Launches with $55 Million Series A Financing Led by Third Rock Ventures to Discover and Develop Highly Specific Immunotherapies Using a Novel Technology Platform
 
 

This links to an external website.

Continue